Temporal Trends and Outcomes of TAVR in Bicuspids: Are We Any Better?

This large registry has shown bicuspid aortic stenosis (AS) patients have similar mortality with transcatheter aortic valve replacement (TAVR) compared against surgical valve replacement (SAVR). TAVR outcomes in this population are not only similar to SAVR outcomes, but also to TAVR outcomes in patients with conventional aortic valve anatomy. Despite the good news, these outcomes<a href="https://solaci.org/en/2019/11/15/temporal-trends-and-outcomes-of-tavr-in-bicuspids-are-we-any-better/" title="Read more" >...</a>

Meta-Analysis of Large TAVR Studies on Low-Risk: Evidence is Consistent

This meta-analysis which included the 4 large randomized studies on transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) in low-risk patients recently published in JACC, showed TAVR is associated with significant lower mortality compared against SAVR at one year follow up. These results add to the mounting evidence showing that when it<a href="https://solaci.org/en/2019/10/28/meta-analysis-of-large-tavr-studies-on-low-risk-evidence-is-consistent/" title="Read more" >...</a>

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

MIDAS Strategy: Minimizing Implantat Depth According to Membranous Septum

Permanent pacemaker implantation following transcatheter aortic valve replacement (TAVR) continues to be one of the most frequent complications. Even though its real impact on prognosis continues to be controversial, its impact on healthcare cost is out of the question, in addition to being uncomfortable for patients. This study, soon to be published in J Am<a href="https://solaci.org/en/2019/10/18/midas-strategy-minimizing-implantat-depth-according-to-membranous-septum/" title="Read more" >...</a>

TAVR Offers Better Quality of Life to Low Risk Patients

Courtesy of Dr. Carlos Fava. As we all know, TAVR is gaining ground fast in the lower risk patient population, but in addition to analyzing the most important events, researchers are increasingly looking at health status, not only at hospital level, but also after one year. This study looked into PARTNER 3 patient health status<a href="https://solaci.org/en/2019/10/16/tavr-offers-better-quality-of-life-to-low-risk-patients/" title="Read more" >...</a>

TCT 2019 | PCI in Stable CAD. Prior TAVR, with TAVR or Never?

Courtesy of SBHCI. This interesting study presented at TCT 2019 and simultaneously published in Am J Cardiol tells us PCI in stable coronary artery disease cannot lower risk in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Unless patients are symptomatic, most coronary artery lesions do not need revascularization according to researchers.<a href="https://solaci.org/en/2019/10/10/tct-2019-pci-in-stable-cad-prior-tavr-with-tavr-or-never/" title="Read more" >...</a>

TCT 2019 | FORZA: OCT vs FFR to Define Intermediate Lesions: Anatomy or Function?

Courtesy of SBHCI.  Both fractional flow reserve (FFR) and optimal coherence tomography (OCT) can be useful to help define intermediate coronary lesions and optimize PCI outcomes. The FORZA study presented at San Francisco TCT 2019 scientific sessions simultaneously published in JACC randomized patients with intermediate lesions 1:1 to FFR vs OCT. For the FFR arm,<a href="https://solaci.org/en/2019/10/01/tct-2019-forza-oct-vs-ffr-to-define-intermediate-lesions-anatomy-or-function/" title="Read more" >...</a>

TCT 2019 | PARTNER 3: Obvious Short-Term Quality of Life Improvement, but What Happens Afterwards?

Courtesy of SBHCI. Patients with severe aortic stenosis and low surgical risk showed decreased mortality, stroke, and heart failure hospitalization at one year with transcatheter aortic valve replacement compared with surgery. Improved quality of life may seem an obvious consequence, but until now that was mere speculation. This work, presented at the TCT 2019 Scientific Sessions<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-3-obvious-short-term-quality-of-life-improvement-but-what-happens-afterwards/" title="Read more" >...</a>

TCT 2019 | PARTNER 2A at 5 Years: In Intermediate-Risk Patients, TAVR Is Still Head-to-Head with Surgery

Courtesy of the SBHCI. The 2-year results of the PARTNER 2A trial showed that transcatheter aortic valve implantation has a result similar to that of surgery in patients with aortic stenosis and intermediate surgical risk. We lacked long-term data, both clinical and related to prosthesis function. Now, at TCT 2019, researchers presented the 5-year data for this<a href="https://solaci.org/en/2019/10/01/tct-2019-partner-2a-at-5-years-in-intermediate-risk-patients-tavr-is-still-head-to-head-with-surgery/" title="Read more" >...</a>

TCT 2019 | PORTICO: This vs. Any Other Valve Available in the Market

Courtesy of SBHCI. This work, presented at the TCT 2019 Scientific Sessions, showed the 30-day safety and 1-year efficacy of self-expanding prosthesis Portico compared with all valves approved by the US Food and Drug Administration (FDA) for the treatment of patients with severe aortic stenosis and high surgical risk. Between 2014 and 2019, researchers enrolled 750 patients<a href="https://solaci.org/en/2019/09/30/tct-2019-portico-this-vs-any-other-valve-available-in-the-market/" title="Read more" >...</a>

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31